{
  "patientId": "MF001",
  "demographics": {
    "name": "Olivia Chen",
    "dob": "1968-07-11",
    "gender": "Female",
    "address": "101 Main St, Anytown, USA",
    "phone": "555-1010",
    "insurance": "Aetna - Policy #AETN-OC-196807",
    "referringPhysician": "Dr. Laura Davis (Dermatology)",
    "emergencyContact": "Mark Chen (Husband) - 555-1011",
    "advanceDirectives": "Full Code. On file, verified 01/18/2025.",
    "supportServices": "Connected with Cutaneous Lymphoma Foundation for patient resources. Social work engaged for support during long treatment course. Nutritional support consult for managing fatigue and potential appetite changes.",
    "mobility": "Independent, Ambulatory. ECOG Performance Status 1 (due to pruritus and skin discomfort)."
  },
  "diagnosis": {
    "primary": "Mycosis Fungoides (Cutaneous T-Cell Lymphoma)",
    "datePathologicDiagnosis": "03/01/2024 (Skin Biopsy)",
    "pathologicStage": "Stage IB (T2b N0 M0 B0)",
    "symptomsAtPresentation": "Patient presented with a multi-year history of a progressive skin rash, initially thought to be eczema. Over the past year, lesions evolved into widespread, thick, erythematous plaques covering an estimated >50% of her Body Surface Area (BSA). She reports severe, debilitating pruritus (itching) that interferes with sleep and daily activities.",
    "pathologyFindings": [
      "Skin Punch Biopsy (03/01/2024): Histologic and immunophenotypic findings are consistent with Mycosis Fungoides, patch/plaque stage. Sections show band-like lymphocytic infiltrate in the papillary dermis with epidermotropism and Pautrier's microabscesses. The dermal infiltrate is composed predominantly of atypical CD3+, CD4+ T-cells with loss of CD7."
    ],
    "priorTreatmentSummary": "Patient has been managed by dermatology for the past year. She has failed to achieve a durable response with high-potency topical steroids and has shown disease progression despite a 3-month course of narrowband UVB phototherapy.",
    "relevantHistory": "No other significant past medical history. No family history of lymphoma. Works as a librarian.",
    "baselineStatus": "ECOG 1. Skin is covered in indurated plaques with significant excoriations from scratching. Pruritus is rated 9/10. Patient is emotionally distressed due to symptoms and appearance."
  },
  "treatmentPlan": {
    "radOnc": "Dr. Samuel Green",
    "dermatologist": "Dr. Laura Davis",
    "treatmentSite": "Total Skin",
    "intent": "Disease control and palliation of symptoms (primarily pruritus).",
    "modality": "Total Skin Electron Beam Therapy (TSEBT)",
    "totalDose": "36 Gy",
    "fractionation": "36 fx",
    "rtRxDetails": "36 Gy in 36 fractions (1 Gy/fx), delivered 4 times per week over 9 weeks.",
    "targetVolumeSummary": "The target volume is the entire skin surface, from the vertex of the scalp to the soles of the feet.",
    "techniqueSummary": "Stanford Technique utilizing 6 dual-fields (AP/PA, RAO/LPO, LAO/RPO). Patient stands on a rotating platform at an extended SSD. This technique combines large electron fields to deliver a uniform dose to the entire skin surface while minimizing dose to underlying tissues.",
    "concurrentChemo": "None",
    "medications": [
      "Aquaphor Healing Ointment: Apply liberally to entire body BID-TID.",
      "Triamcinolone 0.1% Cream: Apply to localized areas of intense erythema or pruritus.",
      "Hydroxyzine 25mg PO at bedtime for pruritus and to aid sleep.",
      "Prophylactic antibacterial soap (e.g., Hibiclens) for washing to reduce infection risk."
    ],
    "therapistAlerts": [
      "TSEBT is a physically demanding setup. Assist patient as needed to achieve all 6 standing positions.",
      "Verify placement of all shielding daily: internal eye shields (requires RN/MD assistance), lead nail shields for fingers and toes.",
      "This is a long treatment course. Monitor for fatigue and skin toxicity progression. Patient may become discouraged.",
      "Weekly in-vivo dosimetry (TLDs/OSLDs) must be placed at designated sites to verify dose. Coordinate with physics.",
      "High risk of generalized, severe dermatitis. Patient may feel cold during treatment; provide blankets between fields."
    ]
  },
  "radiationOncologyData": {
    "ctSimulation": {
      "simulationDate": "01/20/2025",
      "setupInstructions": "Clinical simulation for TSEBT. Patient stands on a rotating platform at an extended distance from the machine (380 cm). Patient holds various positions to expose all skin surfaces for the 6 dual fields.",
      "immobilization": "Standing position with support frame and overhead straps.",
      "referenceMarks": "N/A (alignment is to room lasers and patient position, not tattoos).",
      "scanner": "N/A (Clinical setup)",
      "ctNotes": "Patient measured for manual dose calculations. The 6 treatment positions of the Stanford technique were practiced and confirmed. In-vivo dosimetry (TLD/OSLD) placement locations were determined to verify dose during treatment (forehead, chest, abdomen, thigh, back, calf). Custom lead shields for fingernails and toenails were created. Patient fitted for internal eye shields."
    },
    "dosimetry": {
      "planId": "OCMF001_TSEBT",
      "planStatus": "Final - Approved by Dr. Samuel Green (01/22/2025)",
      "rx": "36 Gy / 36 fx",
      "technique": "TSEBT - Stanford Technique",
      "energy": "6 MeV",
      "numberOfFieldsOrArcs": 6,
      "tps": "Manual Calculation & In-Vivo Dosimetry Verification",
      "algorithm": "Manual/Measured Data",
      "constraints": "Lens dose < 2 Gy (achieved <1 Gy with shields); Fingernails/Toenails dose < 5 Gy (achieved <3 Gy with shields).",
      "planNotes": "Standard dose Stanford 6-field technique TSEBT for mycosis fungoides. Dose will be verified weekly with TLDs. Shielding for eyes and nails to be used daily.",
      "igrtProtocol": {
        "frequency": "Daily",
        "type": "Clinical Setup Verification",
        "alignment": "Alignment to room lasers and floor markings for each of the 6 standing positions. Visual check of patient posture and stability.",
        "tolerances": "N/A (Positional verification)"
      },
      "qaChecks": [
        { "date": "2025-01-22", "type": "TSEBT Beam Calibration & Uniformity Check", "by": "Medical Physicist (SD)", "result": "Pass. Beam output and field flatness meet criteria for extended SSD treatment." }
      ],
      "fieldDetails": [
        { "fieldName": "Dual Field 1 (AP/PA)", "fieldSize": "Open Field", "gantryAngle": "Dual Gantry Angles (e.g., 270 +/- 20 deg)", "energy": "6 MeV", "ssd": "Extended SSD (~380 cm)" },
        { "fieldName": "Dual Field 2 (RAO/LPO)", "fieldSize": "Open Field", "gantryAngle": "Dual Gantry Angles", "energy": "6 MeV", "ssd": "Extended SSD (~380 cm)" },
        { "fieldName": "Dual Field 3 (LAO/RPO)", "fieldSize": "Open Field", "gantryAngle": "Dual Gantry Angles", "energy": "6 MeV", "ssd": "Extended SSD (~380 cm)" }
      ]
    },
    "treatmentDelivery": {
      "fractions": [
        { "fractionNumber": 1, "totalFractions": 36, "date": "2025-01-27", "machine": "LINAC 1 (TSEBT Mode)", "therapistInitials": "JL, MW",
          "recordedFields": [{ "fieldName": "All 6 Positions", "deliveredMu": "Calibrated Daily Dose" }],
          "energiesUsed": "6 MeV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Support frame, straps", "setupAdjustments": "None", "organTargetChecks": "Eye and nail shields confirmed in place.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "Therapist",
          "patientTolerance": "Good", "generalSideEffects": "None", "siteSpecificSideEffects": "None", "painAssessment": "Pruritus 9/10", "patientConcerns": "Anxious about the standing positions.", "instructionsGiven": "Reassured patient. Reinforced skin care instructions.", "billingCodes": "77422, 77427", "dailyNotes": "First TSEBT treatment. Patient was cooperative and able to hold all positions. TLDs placed for first week dose verification."
        },
        { "fractionNumber": 12, "totalFractions": 36, "date": "2025-02-17", "machine": "LINAC 1 (TSEBT Mode)", "therapistInitials": "JL, MW",
          "recordedFields": [{ "fieldName": "All 6 Positions", "deliveredMu": "Calibrated Daily Dose" }],
          "energiesUsed": "6 MeV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Support frame, straps", "setupAdjustments": "None", "organTargetChecks": "Shielding verified.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "Therapist",
          "patientTolerance": "Good", "generalSideEffects": "Mild fatigue", "siteSpecificSideEffects": "Moderate generalized erythema (Grade 1-2). Plaques beginning to flatten.", "painAssessment": "Pruritus 5/10", "patientConcerns": "Skin is very red and dry.", "instructionsGiven": "Reinforce aggressive moisturizing. Avoid hot water.", "billingCodes": "77422, 77427", "dailyNotes": "OTV today. Excellent clinical response noted with flattening of plaques and improvement in pruritus. Skin reaction is as expected."
        },
        { "fractionNumber": 24, "totalFractions": 36, "date": "2025-03-10", "machine": "LINAC 1 (TSEBT Mode)", "therapistInitials": "JL, MW",
          "recordedFields": [{ "fieldName": "All 6 Positions", "deliveredMu": "Calibrated Daily Dose" }],
          "energiesUsed": "6MeV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Support frame, straps", "setupAdjustments": "None", "organTargetChecks": "Shielding verified.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "Therapist",
          "patientTolerance": "Fair", "generalSideEffects": "Significant fatigue.", "siteSpecificSideEffects": "Severe erythema with patchy moist desquamation (Grade 2-3 dermatitis), particularly in skin folds (axilla, groin). Anhidrosis (inability to sweat).", "painAssessment": "Pruritus 2/10", "patientConcerns": "Skin is very sore. Feels very tired.", "instructionsGiven": "RN provided wound care instructions for areas of moist desquamation. Advised patient to rest as much as possible.", "billingCodes": "77422, 77427", "dailyNotes": "OTV today. Patient having significant but expected skin toxicity. Pruritus is dramatically improved, which is a major goal. Supportive care is key."
        },
        { "fractionNumber": 36, "totalFractions": 36, "date": "2025-03-31", "machine": "LINAC 1 (TSEBT Mode)", "therapistInitials": "JL, MW",
          "recordedFields": [{ "fieldName": "All 6 Positions", "deliveredMu": "Calibrated Daily Dose" }],
          "energiesUsed": "6MeV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Support frame, straps", "setupAdjustments": "None", "organTargetChecks": "Final check of shielding.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "SG (Physician)",
          "patientTolerance": "Fair", "generalSideEffects": "Significant fatigue.", "siteSpecificSideEffects": "Widespread Grade 3 dermatitis with moist desquamation. Plaques are completely flat. Pruritus is gone.", "painAssessment": "Pruritus 0/10; Skin soreness 4/10", "patientConcerns": "Relieved to be finished. Concerned about skin healing.", "instructionsGiven": "Provided detailed end-of-treatment wound care instructions. Explained that skin will slowly heal over the next 4-6 weeks. Follow-up appointments scheduled.", "billingCodes": "77422, 77427", "dailyNotes": "Final TSEBT treatment delivered. Patient has had an excellent clinical response. Will require close follow-up for skin healing."
        }
      ]
    }
  },
  "progressNotes": [
    { "date": "01/05/2025", "author": "Dr. Laura Davis (Derm)", "type": "Referral Note", "summary": "56yo F with Stage IB Mycosis Fungoides, extensive plaque-stage disease (>50% BSA). Her disease has been refractory to high-potency topical steroids and a full course of narrowband UVB phototherapy. Her pruritus is severe and debilitating, significantly impacting her quality of life. Referring to Radiation Oncology for consideration of Total Skin Electron Beam Therapy (TSEBT)." },
    { "date": "01/18/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "Initial Consult", "summary": "Patient referred for TSEBT for refractory Stage IB MF. Exam confirms widespread indurated plaques. Staging workup is negative for extracutaneous disease. She is an excellent candidate for TSEBT. Discussed the procedure in detail (Stanford technique, 36Gy in 36 fractions over 9 weeks), expected toxicities (universal severe dermatitis, fatigue, alopecia, nail changes), and goals of care (disease control, symptom improvement). The patient understands the significant commitment and potential toxicities and wishes to proceed. Simulation scheduled." },
    { "date": "03/10/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "OTV - Week 6", "summary": "Patient has completed 24 of 36 fractions. She is experiencing significant but expected side effects, including Grade 2-3 dermatitis and significant fatigue. However, her clinical response is excellent, with near-complete flattening of all plaques and dramatic improvement in her pruritus. She is managing her skin care diligently. We will continue with the current plan and supportive care." },
    { "date": "03/31/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "End of Treatment Note", "summary": "Olivia has completed her full course of 36 Gy TSEBT. She has achieved a complete clinical response, with resolution of all skin plaques. Her pruritus is resolved. She has significant Grade 3 dermatitis, which will now begin the healing process over the next several weeks. She will have very close follow-up with our nursing team and dermatology for wound care and monitoring. Overall, an excellent response to a challenging treatment." }
  ]
}
